title: [Survival of breast cancers patients with meningeal carcinoma].
abstract: OBJECTIVE
  Among all solid tumors breast cancer is the most common cause of meningeal carcinomatosis (MC). The purpose of this study was to analyze clinical and biological responses as well as overall survival in MC patients (pts) of breast primary treated with intrathecal methotrexate (MTX).
  
  
  METHODS
  Single-center retrospective series of MC pts treated between 2000 and 2007. Chemotherapy regimen was: MTX (15 mg/day; day 1-5) and depomedrol (40 mg, day 1) plus leucoverin (12 mg IV or 25 mg PO; day 1-5). Treatment cycles were repeated every 2 weeks. The survival was analyzed according to the characteristics of the tumor considering clinical and cytological response rates to treatment.
  
  
  RESULTS
  The median survival was 4.5 months (range 0-53). In multivariate analysis, poor prognostic factors at diagnosis were: Performans status greater than 2 [P = 0.006, RR = 0.33 (0.15-0.71)], more than three chemotherapy regimens before MC diagnosis [P = 0.03, RR = 0.40 (0.19-0.93)], negative hormone receptor status [P = 0.02, RR = 0.4 (0.19-0.90)] and high Cyfra-21-1 level [P = 0.048, RR = 0.09-0.99]. The clinical progression after one cycle and the biological response after two cycles were independently correlated with OS [P<0.001, RR = 0.09 (0.02–0.37) and P = 0.003, RR = 3.6 (1.5–8.5), respectively]. A prognostic score designed to define three groups of patients is proposed.
  
  
  CONCLUSIONS
  Although prognosis of patients with MC is poor, 1-year overall survival rate is 25%. The proposed prognostic score may be helpful in decision but warrants further assessment and validation in prospective trials.
authors.affiliation: Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France. lngauthier@gmail.com
authors.forename: Hélène
authors.initials: H
authors.lastname: Petithuguenin Gauthier
authors.forename: Marie-Noëlle
authors.initials: MN
authors.lastname: Guilhaume
authors.forename: François-Clément
authors.initials: FC
authors.lastname: Bidard
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Pierga
authors.forename: Véronique
authors.initials: V
authors.lastname: Girre
authors.forename: Paul-Henri
authors.initials: PH
authors.lastname: Cottu
authors.forename: Valérie
authors.initials: V
authors.lastname: Laurence
authors.forename: Alain
authors.initials: A
authors.lastname: Livartowski
authors.forename: Laurent
authors.initials: L
authors.lastname: Mignot
authors.forename: Véronique
authors.initials: V
authors.lastname: Dieras
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D055756:Meningeal Carcinomatosis / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary*; D008577:Meningeal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary*; D008727:Methotrexate / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage; D012189:Retrospective Studies; D014803:Vitamin B Complex
chemical_list: D000964:Antimetabolites, Antineoplastic; D018696:Neuroprotective Agents; D014803:Vitamin B Complex; D002955:Leucovorin; D008775:Methylprednisolone; D008727:Methotrexate